U.S. Senate Schedules Hearing for New FDA Commissioner
美國參議院排定新任食品藥物管理局局長提名聽證會
更新於: 2026年9月19日 上午01:00
The U.S.
美國參議院健康、教育、勞工與退休金委員會（HELP委員會）已排定於2026年9月24日舉行確認聽證會，以評估海蒂·歐文頓（Heidi Overton）博士作為食品藥物管理局（FDA）局長提名人的資格。
Senate Committee on Health, Education, Labor, and Pensions (HELP) has scheduled a confirmation hearing for September 24, 2026, to evaluate Dr.
自馬蒂·馬卡里（Marty Makary）博士於2026年5月辭職後，FDA一直缺乏常任領導人，代理局長凱爾·迪亞曼塔斯（Kyle Diamantas）被迫在此動盪時期管理該機構。
Heidi Overton as the nominee for Commissioner of the Food and Drug Administration (FDA).
歐文頓博士是一位預防醫學醫師，目前擔任白宮國內政策委員會副主任，她正面臨嚴格審視。
Marty Makary in May 2026, leaving acting commissioner Kyle Diamantas to manage the agency during a tumultuous period.
議員們特別關注疫苗政策、米非司酮（mifepristone）的監管以及機構政治化的指控等備受矚目的議題。
Overton, a preventive medicine physician and current deputy director of the White House Domestic Policy Council, faces significant scrutiny.
由於HELP委員會僅擁有微弱的共和黨多數優勢，預計即將舉行的聽證會將是一場高風險的考驗。
Her nomination comes at a difficult time for the FDA, which has seen over 3,000 employees depart within the last year.
新任局長將繼承穩定員工士氣、清理招聘積壓工作以及定義美國公共衛生監管未來的關鍵任務。
Lawmakers are particularly concerned about high-profile issues such as vaccine policy, the regulation of mifepristone, and allegations of agency politicization.
Specifically, committee chair Bill Cassidy has expressed reservations regarding Dr.
Overton’s previous work on vaccine recommendations.
